More about chloroquine and hydroxychloroquine, CEBM
VERDICT: The hypothesis that the 4-aminoquinolines chloroquine and hydroxychloroquine may be beneficial in the treatment of COVID-19 is a weak one, based on poor mechanistic reasoning and inconsistent results of studies in vitro, in laboratory animals, and in humans. It is likely that even if chloroquine and hydroxychloroquine are effective in COVID-19, the beneficial effects will be small. The risks of adverse reactions to these drugs may be increased in patients who are acutely ill with severe COVID-19, in many of whom high doses are being used. Macrolide antibacterial drugs, such as azithromycin, clarithromycin, ery...
Source: Current Awareness Service for Health (CASH) - June 1, 2020 Category: Consumer Health News Source Type: news

Ketek (Telithromycin) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 19, 2016 Category: Drugs & Pharmacology Source Type: news

Good Clinical Practice: From Review to Application
In clinical research many rules and regulations exist to govern the way research is conducted and to protect those patients who are participating in research. One of the standard principles directing clinical research is Good Clinical Practice. Good clinical practice is more than any one document; rather, it is a collective compilation of many thoughts, ideas and learning moments spanning the globe over. Good clinical practice is an attitude of credible excellence in research that provides a standard for clinical study design, implementation, conduct and analysis. Furthermore, good clinical practice is a mind-set that is a...
Source: Mass Device - April 15, 2016 Category: Medical Equipment Authors: MassDevice Tags: Blog IMARC Source Type: news

Rapamune (sirolimus) tablets and oral solution - Pfizer Limited - Revised SPC
Source: eMC (electronic Medicines Compendium) Area: Other Library Updates> SPC Changes Section 4.5 Interaction with other medicinal products and other forms of interaction has been updated to include potential interactions with CYP3A4 inhibitors, which may decrease the metabolism of sirolimus and increase sirolimus blood levels. Such inhibitors include e.g. certain antifungals (e.g. clotrimazole, fluconazole, itraconazole, voriconazole), certain antibiotics (e.g.  troleandomycin, telithromycin, clarithromycin), certain protease inhibitors (e.g. ritonavir, indinavir, boceprevir, telaprevir),  nicardipine, brom...
Source: NeLM - SPC Changes - March 1, 2013 Category: Drugs & Pharmacology Source Type: news